Company Snapshot: CNMD  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


CONMED Corporation Comments on Expected Fourth Quarter Results

           - A Conference Call is Scheduled for 10:00 AM (Eastern),
                        Today for Further Discussion -

    UTICA, N.Y., Jan. 8 /PRNewswire-FirstCall/ --
CONMED Corporation (Nasdaq: CNMD) announced today that sales for the three
months ended December 31, 2002 reached a record quarterly amount of
approximately $115.3 million and unaudited sales for the full year 2002
reached an annual record of approximately $453.1 million.  While sales reached
record levels on a quarterly and yearly basis, revenues were still somewhat
lower than the Company's expectations discussed on the October 17, 2002
quarterly earnings conference call. Based on the information currently
available, the Company now anticipates that its diluted earnings per share for
the fourth quarter of 2002 will be approximately $0.31 - $0.33 and
approximately $1.30-$1.32 per diluted share before extraordinary item for the
full year 2002.  The Company will announce full results for the fourth quarter
of 2002 and full year 2002 on February 6, 2003.
    By product line, orthopedic product sales in the fourth quarter were
generally flat, although large bone powered instrument sales grew 19% on the
strength of the Company's sales of the PowerPro(R) battery instruments.
Electrosurgery revenues grew 6%, Patient Care revenues grew 1% and Endoscopy
products revenues were flat.  For the full year, Arthroscopy revenues grew 4%,
Powered Surgical Instrument revenues were flat, Electrosurgery revenues grew
4%, Patient Care revenues grew 1% and Endoscopy products revenues grew 61%, of
which 7% represented organic growth.  Overall, sales grew 1.9% in the fourth
quarter of 2002 (as compared to the fourth quarter of 2001) and 5.7% for the
full year 2002.
    Arthroscopy revenues were weaker than anticipated, in part, due to flat
sales of video systems in the quarter.  For the year 2002, however, video
systems grew in excess of 11%.  Because of the nature of sales for capital
equipment, quarterly sales of video products are susceptible to fluctuations
based on the timing of closing individual sales contracts.  Powered Surgical
Instrument sales were also flat, as gains in large bone products, led by
PowerPro(R), were offset by sales declines in the small bone and specialty
product groups.  The Company anticipates upgrading the product offering in the
small bone line in 2003.
    Mr. Joseph J. Corasanti, President and COO of CONMED, stated, "Sales in
our fourth quarter each year are typically the best of any quarter.  While
this continued to be true in 2002, we did not experience as large an increase
in revenues as we had anticipated.  This shortfall was centered around capital
equipment products such as our Powered Surgical instruments and our video
systems.  While evaluation activity continues to be strong, many potential
transactions were delayed by our customers."
    Mr. Corasanti added, "Although we are disappointed by the Company's sales
growth in the fourth quarter, we continue to be optimistic about our prospects
for 2003.  We expect that the PowerPro(R) battery powered surgical instrument
sales will continue to advance, our new electrosurgical generators will be
ready for shipment in the first quarter of 2003, we have additional new
products ready for launch in 2003, and our acquisitions of Core Dynamics
(announced in an earlier press release today), ValMed and Nortrex will add
additional substance to our surgical product offerings.  We continue to
believe that our 2003 organic sales increase will approximate 6% over 2002 (8%
growth including the acquisitions) and that our earnings per share should
increase approximately 15% compared to 2002 earnings per share (excluding one-
time acquisition related expenses for Core Dynamics)."
    CONMED will hold a conference call at 10:00 am today to further discuss
the fourth quarter 2002 anticipated results.  Interested parties may access
the conference call by calling 888-753-5576 or 706-643-7656.  The conference
call will also be available at the investor relations section of CONMED's
website -- http://www.conmed.com.  The conference call will be available by
replay until January 9, 2003 by dialing 800-642-1687 or 706-645-9291
(code:7470107) or at the CONMED website.

    CONMED is a medical technology company specializing in instruments,
implants, and video equipment for arthroscopic sports medicine, and powered
surgical instruments, such as drills and saws, for orthopedic, ENT, neuro-
surgery, and other surgical specialties.  The Company is also a leading
developer, manufacturer and supplier of RF electrosurgery systems used
routinely to cut and cauterize tissue in nearly all types of surgical
procedures worldwide, endoscopy products such as trocars, clip appliers,
scissors, and surgical staplers.  The Company offers integrated operating room
design and intensive care unit service managers.  The Company also
manufactures and sells a full line of  ECG electrodes for heart monitoring and
other patient care products.  Headquartered in Utica, New York, the Company's
2,500 employees distribute its products worldwide from ten manufacturing
locations.

    This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties.  The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis.  The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures.  The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct.  In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2001 and the
Prospectus dated May 22, 2002; (iii) cyclical purchasing patterns from
customers, end-users and dealers;  (iv) timely release of new products, and
acceptance of such new products by the market; (v) the introduction of new
products by competitors and other competitive responses; (vi) the possibility
that any new acquisition or other transaction may require the Company to
reconsider its financial assumptions and goals/targets; and/or (vii) the
Company's ability to devise and execute strategies to respond to market
conditions.


SOURCE CONMED Corporation




Back to Topback to top

Related links:
  • http://www.conmed.com
    Company News On-Call:
  • http://www.prnewswire.com/comp/201850.html
    CONTACT:
    Robert Shallish, Chief Financial Officer of
    CONMED Corporation, +1-315-624-3206; Investors - Lauren Levine,
    or Lanie Fladell; Media - Sean Leous +1-212-850-5600, all of FD
    Morgen-Walke, for CONMED Corporation